TTLL8: A Potential Drug Target and Biomarker (G164714)

Target Name: TTLL8

NCBI ID: G164714

TTLL8

TTLL8: A Potential Drug Target and Biomarker

TTLL8, short for tissue-targeted latency-promoting leukemia 8, is a protein that is expressed in various tissues, including the brain, spleen, and lymph nodes. It is a member of the latency-promoting leukemia 8 (LPL) family, which is known for promoting the survival and proliferation of cancer cells. TTLL8 has been identified as a potential drug target and biomarker in various diseases, including cancer.

The discovery of TTLL8 as a potential drug target comes from a study by the National Cancer Institute (NCI) and the National Institute of Mental Health (NIMH). The researchers found that TTLL8 was highly expressed in the brain and spleen of various cancer types, including lung, breast, and ovarian cancers. They also found that inhibiting TTLL8 reduced the growth and migration of cancer cells.

The potential use of TTLL8 as a drug target is based on its ability to promote the survival and proliferation of cancer cells. This is because TTLL8 is a protein that is expressed in various tissues, including the brain, spleen, and lymph nodes, which suggests that it may be involved in the development and progression of cancer. The fact that TTLL8 is highly expressed in the brain and spleen of various cancer types also suggests that it may be involved in the treatment of these cancers.

In addition to its potential as a drug target, TTLL8 has also been identified as a biomarker. This is because it is expressed in various tissues and can be used as a protein biomarker for cancer. The researchers found that TTLL8 was expressed in various tissues, including the brain, spleen, and lymph nodes, and that it was able to be detected using various techniques, such as mass spectrometry and western blotting.

The potential use of TTLL8 as a biomarker for cancer comes from its ability to be detected in various tissues and its potential to serve as a diagnostic marker for cancer. The fact that TTLL8 is expressed in the brain and spleen of various cancer types also suggests that it may be a useful biomarker for the treatment of these cancers.

TTLL8 has also been shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. This suggests that it may be a useful target for drugs that are designed to disrupt these processes and treat cancer.

In conclusion, TTLL8 is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer. Its ability to promote the survival and proliferation of cancer cells makes it a promising target for drugs that are designed to disrupt its functions. The fact that TTLL8 is expressed in various tissues, including the brain and spleen, also suggests that it may be a useful biomarker for the treatment of these cancers. Further research is needed to fully understand the potential of TTLL8 as a drug target and biomarker.

Protein Name: Tubulin Tyrosine Ligase Like 8

Functions: Monoglycylase which modifies both tubulin and non-tubulin proteins, adding a single glycine to the gamma-carboxyl groups of specific glutamate residues to generate monoglycine side chains within the C-terminal tail of target proteins. Not involved in elongation step of the polyglycylation reaction. Preferentially monoglycylates alpha-tubulin over beta-tubulin. Together with TTLL3, mediates microtubule glycylation of primary and motile cilia, which is essential for their stability and maintenance. Together with TTLL3, glycylates sperm flagella which regulates axonemal dynein motor activity, thereby controlling flagellar beat, directional sperm swimming and male fertility. Monoglycylates non-tubulin proteins such as ANP32A, ANP32B, SET, NCL and NAP1

The "TTLL8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTLL8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets